Bioventus (BVS) EBIT Margin (2020 - 2026)

Bioventus' EBIT Margin history runs 7 years deep, the most recent figure standing at 6.37% for Q1 2026.

• Quarterly EBIT Margin rose 244.0% year-over-year to 6.37% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 9.98% (up 1267.0% YoY) and the FY2025 annual result came in at 9.5%, up 1215.0% from the prior year.
• EBIT Margin was 6.37% for Q1 2026 at Bioventus, down from 12.34% in the prior quarter.
• Across five years, EBIT Margin topped out at 12.44% in Q2 2025 and bottomed at 98.58% in Q4 2022.
• A 5-year average of 9.84% and a median of 2.62% in 2024 frame the typical range for EBIT Margin.
• Annual changes were most pronounced in 2022 — EBIT Margin sank 9762 bps — and 2023, when it soared 10058 bps.
• Bioventus' EBIT Margin stood at 12.43% in 2022, then surged by 107 bps to 0.86% in 2023, then surged by 483 bps to 5.01% in 2024, then soared by 146 bps to 12.34% in 2025, then slumped by 48 bps to 6.37% in 2026.
• Business Quant data shows BVS's EBIT Margin at 6.37% in Q1 2026, 12.34% in Q4 2025, and 8.12% in Q3 2025.